---
title: "Sino Biological Inc. (301047.SZ)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/301047.SZ.md"
symbol: "301047.SZ"
name: "Sino Biological Inc."
industry: "Biotechnology"
datetime: "2026-05-20T22:41:44.005Z"
locales:
  - [en](https://longbridge.com/en/quote/301047.SZ.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/301047.SZ.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/301047.SZ.md)
---

# Sino Biological Inc. (301047.SZ)

## Company Overview

Sino Biological,Inc. provides recombinant protein and antibody reagents for life science researchers in China and internationally. The company offers recombinant proteins, antibodies, cDNA clones, kits, serum-free media, protein modification, qPCR primers, cell lysates, and purification reagents. It also provides comprehensive solutions, including autoimmune disease research, kinase drug discovery, cytokine and growth factor, SARS-CoV-2 variants research, comprehensive CAR-T therapy, 3D organoids research, ADC development, influenza vaccine development, and multispecific antibody development solutions, as well as solutions for MSCs therapy and in vitro efficacy evaluation.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | CN Market |
| Website | [www.sinobiological.com](https://www.sinobiological.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: B
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-20T04:30:09.000Z

**Overall: B (0.38)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 13 / 81 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: B

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 18.01% |  |
| Net Profit YoY | 56.00% |  |
| P/B Ratio | 1.56 |  |
| Dividend Ratio | 9.06% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 8334751899.35 |  |
| Revenue | 728982671.24 |  |

#### Multi Score Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 2.83% | C |
| Profit Margin | 21.61% | A |
| Gross Margin | 75.46% | A |
| Revenue YoY | 18.01% | B |
| Net Profit YoY | 56.00% | B |
| Total Assets YoY | -8.21% | E |
| Net Assets YoY | -7.82% | D |
| Cash Flow Margin | 112.44% | C |
| OCF YoY | 18.01% | B |
| Turnover | 0.13 | E |
| Gearing Ratio | 3.91% | A |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Sino Biological Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "18.01%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "56.00%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "1.56",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "9.06%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "8334751899.35",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "728982671.24",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "B",
      "indicators": [
        {
          "name": "ROE",
          "value": "2.83%",
          "rating": "C"
        },
        {
          "name": "Profit Margin",
          "value": "21.61%",
          "rating": "A"
        },
        {
          "name": "Gross Margin",
          "value": "75.46%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "18.01%",
          "rating": "B"
        },
        {
          "name": "Net Profit YoY",
          "value": "56.00%",
          "rating": "B"
        },
        {
          "name": "Total Assets YoY",
          "value": "-8.21%",
          "rating": "E"
        },
        {
          "name": "Net Assets YoY",
          "value": "-7.82%",
          "rating": "D"
        },
        {
          "name": "Cash Flow Margin",
          "value": "112.44%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "18.01%",
          "rating": "B"
        },
        {
          "name": "Turnover",
          "value": "0.13",
          "rating": "E"
        },
        {
          "name": "Gearing Ratio",
          "value": "3.91%",
          "rating": "A"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 52.38 | 23/81 | 81.69 | 69.55 | 62.64 |
| PB | 1.54 | 14/81 | 1.70 | 1.59 | 1.52 |
| PS (TTM) | 11.32 | 53/81 | 14.25 | 13.50 | 12.55 |
| Dividend Yield | 9.16% | 1/81 | 7.05% | 6.73% | 1.45% |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Sunshine Guojian Pharmaceutical (688336.SH) | A | A | B | A | B | A |
| 02 | AMOYTOP (688278.SH) | A | A | A | A | B | A |
| 03 | BeOne Medicines (688235.SH) | B | A | B | C | A | B |
| 04 | RemeGen (688331.SH) | A | A | C | C | B | B |
| 05 | InnoCare Pharma (688428.SH) | B | A | D | B | B | B |

## Institutional View

### Analyst Rating Distribution

> As of 2026-02-13T16:00:00.000Z

Total Analysts: **1**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 1 | 100% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 67.72 |
| Highest Target | 78.00 |
| Lowest Target | 78.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/301047.SZ/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/301047.SZ/norm.md)
- [Related News](https://longbridge.com/en/quote/301047.SZ/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/301047.SZ/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**